The efficacy of GRAS4T was further evaluated using the human HER2-positive breast tumor (HER2+) dataset [45], which used different spatial technologies (spatial transcriptomics) compared to the DLPFC dataset. The gene discussed is ERBB2; the disease is breast neoplasm.